Trial Profile
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2014
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Nov 2014 New trial record